Isomorphic Labs is the secretive AI life sciences startup spun out of Google DeepMind with the goal of solving all disease ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

金融时报消息，总部位于英国伦敦的 Isomorphic Labs 宣布完成6 亿美元融资。本次由 Thrive Capital 领投，现有投资者G谷歌的母公司Alphabet、GV也进行了追加投资。这笔资金将用于进一步开发其人工智能驱动的药物设计技术 ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These include oncology and immunology, the primary focuses of the company's internal ...

On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup.